HF17 Summary

• Prohibits manufacturers from imposing excessive price increases on generic or off-patent drugs, defined as increases exceeding 15% annually or 40% over three years (adjusted for inflation) plus $30 minimum threshold per 30-day supply.

• Authorizes the attorney general to investigate violations, compel manufacturers to submit cost statements, and pursue remedies including injunctions, civil penalties up to $10,000 per day, and recovery of all revenues from violations.

• Prohibits manufacturers from withdrawing generic or off-patent drugs from the state market to avoid price increase restrictions, with a $500,000 penalty for non-compliance.

• Establishes a 9-member Prescription Drug Affordability Board appointed by the governor and legislative leaders to conduct cost reviews of brand name drugs, biologics, and biosimilars, with authority to set upper payment limits on drugs creating affordability challenges.

• Creates a 12-member Prescription Drug Affordability Advisory Council representing patients, providers, employers, manufacturers, and health plans to advise the board on drug cost issues.